- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Strides Pharma raises Rs 1,415 crore in series B, C funding
New Delhi: Strides Pharma Science on Friday said its biotech arm Stelis Biopharma concluded its series B and Series C fund raise for a cumulative amount of USD 195 million (approx Rs 1,415 crore).
Post money valuation for Stelis will be pegged at USD 350 million.
Stelis Biopharma has successfully concluded its series B and Series C fund raise for a cumulative amount of USD 195 million, Strides Pharma Science said in a regulatory filing.
Strides Pharma Science with the current capital raise, Stelis is now well positioned to pursue its growth initiatives and scale its business model to deliver promising returns in the coming years.
Strides said it will demerge and list its biopharma business under Stelis on a standalone basis enabling significant value unlocking for Strides shareholders.
Strides said Stelis as part of its series B issue will raise USD 70 million from existing investors at the current pre-money valuation of USD 155 million through partly paid shares.
The company has raised an additional USD 125 million through series C funding round including a primary infusion of USD 85 million in the company and a secondary placement of USD 40 million for GMS Holdings, our existing shareholder.
Read also: Strides Pharma Science arm gets USFDA nod for Ibuprofen OTC Oral Suspension
This funding round led by TPG Growth followed by other long-term investors namely, Route One, Think Investments and the Mankekar Family, Stride said, adding that the post money valuation for the business pegged at USD 350 million.
The transaction is subject to approval from shareholders, meeting customary closing conditions and is expected to achieve closure in over 12 months.
Read also: Strides Pharma Science subsidiary gets USFDA nod for Potassium Chloride for Oral Solution
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751